Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-label, Multicenter Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Subjects With Non-transfusion-dependent Thalassemia

Trial Profile

A Phase 2, Open-label, Multicenter Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Subjects With Non-transfusion-dependent Thalassemia

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Jan 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mitapivat (Primary)
  • Indications Alpha-thalassaemia; Beta-thalassaemia; Thalassaemia
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Agios Pharmaceuticals
  • Most Recent Events

    • 11 Jan 2021 According to an Agios Pharmaceuticals media release, data from this study will be submitted for presentation at the European Hematology Association (EHA) Virtual Congress, which will be held from 9th to 17th Jun 2021.
    • 08 Dec 2020 Interim results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
    • 19 Oct 2020 Planned End Date changed from 28 Aug 2022 to 30 Sep 2030.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top